Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Nat Med
.
2024 Jun;30(6):1788-1789.
doi: 10.1038/s41591-024-02890-2.
Authors
Deepak L Bhatt
1
,
Harold E Bays
2
,
Michael Miller
3
,
James E Cain 3rd
4
,
Katarzyna Wasilewska
5
,
Nabil S Andrawis
6
,
Teresa Parli
7
,
Shibao Feng
7
,
Lulu Sterling
7
,
Leo Tseng
7
,
Cynthia L Hartsfield
7
,
Germaine D Agollah
7
,
Hank Mansbach
7
,
John J P Kastelein
8
;
ENTRIGUE Principal Investigators
Affiliations
1
Mount Sinai Heart, Icahn School of Medicine, Mount Sinai Health System, New York City, NY, USA.
[email protected]
.
2
Louisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, Louisville, KY, USA.
3
Corporal Michael J. Crescenz VA Medical Center and Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
4
Family Medicine Clinic Science, Lampasas, TX, USA.
5
ZDROWIE Osteo-Medic, Bialystok, Poland.
6
Manassas Clinical Research Center, Manassas, VA, USA.
7
89bio Inc., San Francisco, CA, USA.
8
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
PMID:
38438737
PMCID:
PMC11186769
DOI:
10.1038/s41591-024-02890-2
No abstract available
Publication types
Published Erratum